Key Highlights

  • Third quarter 2026 net loss widened to $78.1 million from $56.9 million a year earlier.
  • Research and development expense rose to $69.8 million, driven by 4D-150 Phase 3 trials.
  • Cash and marketable securities were $375.0 million as of September 30, 2026.
  • Topline data from the first wet AMD Phase 3 trial is expected in the second quarter of 2027.

4D Molecular Therapeutics (NASDAQ:FDMT) reported third quarter 2026 financial results on November 12, 2026, and outlined its expected milestones for the coming year. The Emeryville, California biotechnology company is developing 4D-150, a gene therapy intended to provide sustained delivery of anti-VEGF Biologics with a single intravitreal injection. The quarter featured higher research spending, a larger net loss and a continued focus on two Phase 3 programs in retinal disease. The company also reported several Leadership and regulatory updates.

Phase 3 Program Timelines

The company said enrollment and randomization are complete in both 4FRONT Phase 3 trials for wet age-related macular degeneration. The North American 4FRONT-1 trial randomized 523 patients in March 2026, with topline data expected in the second quarter of 2027. The global 4FRONT-2 trial randomized 531 patients in August 2026, and its topline data is expected in the second half of 2027.

In diabetic macular edema, 4DMT has started 4SIGHT, a global Phase 3 study of 4D-150 against aflibercept 2 mg in 514 treatment-naive patients. The primary endpoint is non-inferiority in the change in best corrected visual acuity at Week 52. The company also reported updated two-year data from its SPECTRA Part 1 trial in the same indication and said it presented two-year Phase 2b data in wet AMD in July.

The company's trial timelines depend on the readouts of its Phase 3 studies, and the company has said that these data will determine its next regulatory and commercial steps. Management described the 4SIGHT program as an extension of the 4D-150 opportunity into diabetic macular edema, a retinal condition the company characterized as a second multi-billion-dollar market.

Spending, Revenue and Net Loss

Research and development expense was $69.8 million for the third quarter, compared with $49.4 million a year earlier. The company attributed the increase primarily to the execution of its wet AMD Phase 3 trials. General and administrative expense rose to $15.6 million from $11.8 million.

Collaboration and license revenue reached $4.1 million, compared with $0.1 million in the third quarter of 2025, primarily through clinical trial cost sharing and reimbursement from Otsuka Pharmaceutical. The net loss totaled $78.1 million, up from $56.9 million. Cash, cash equivalents and marketable securities stood at $375.0 million, compared with $514.0 million at the end of 2025, and management expects existing resources to fund operations into the second half of 2028.

Research spending has increased as the company runs multiple late-stage trials at the same time. The company noted that its operating plan covers the costs of its current programs and its collaboration arrangements with Otsuka, and the headline summary does not describe new financing in the quarter.

Leadership and Other Pipeline Programs

4DMT appointed Dr. Eric Floyd as Chief Regulatory and Quality Officer. He will oversee regulatory strategy, quality assurance and quality control, and previously held regulatory roles at Silence Therapeutics and Neurogene, as well as senior regulatory and quality positions at Merck, Sanofi and Novartis. The company also hosted an investor day in New York City on October 21, 2026, focused on the wet AMD treatment landscape.

Outside retinal disease, the company said it maintains an active investigational new drug application for 4D-175 in geographic atrophy and is evaluating Options to move that program into the clinic. An update on 4D-710, its cystic fibrosis candidate, is expected at year-end.

The company also reported that patient data from its earlier PRISM study in wet AMD were presented at the American Society of Retina Specialists meeting, covering durable visual acuity results and a reduced treatment burden. Those results were shared at a scientific meeting and are separate from the topline readouts expected in 2027.

Final Word

The third quarter reflects a company directing most of its resources toward late-stage retinal programs, with research spending rising alongside its Phase 3 work. Cash of $375.0 million is lower than the $514.0 million reported at the end of 2025, and the net loss continues to grow as trials advance. Investors will look to the 2027 topline readouts to judge the wet AMD program, and the company has said the expected data will shape its plans for the coming year.